公开(公告)号：US20220185806A1

公开(公告)日：2022-06-16

申请号：US17557215

申请日：2021-12-21

Applicant: FORMA Therapeutics, Inc.

Inventor： Justin Caravella ,  Bingsong Han ,  Cuixian Liu ,  Stephanos Ioannidis ,  Alexandre Joseph Buckmelter ,  David James Richard ,  Matthew W. Martin ,  Steven Mischke ,  Scot Mente

IPC: C07D417/12 ,  C07C261/04 ,  C07D231/40 ,  C07D241/04 ,  C07D265/30 ,  C07D277/46 ,  C07D277/56 ,  C07D417/04

Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments.

公开(公告)号：US20200317658A1

公开(公告)日：2020-10-08

申请号：US16753439

申请日：2018-10-05

Applicant: FORMA Therapeutics, Inc.

Inventor： Justin Caravella ,  Bingsong Han ,  Cuixian Liu ,  Stephanos Ioannidis ,  Alexandre Joseph Buckmelter ,  David James Richard ,  Matthew W. Martin ,  Steven Mischke ,  Scot Mente

IPC: C07D417/12 ,  C07D417/04 ,  C07D277/56 ,  C07D231/40 ,  C07D277/46 ,  C07C261/04 ,  C07D241/04 ,  C07D265/30

Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments.

公开(公告)号：US20220315565A1

公开(公告)日：2022-10-06

申请号：US17668621

申请日：2022-02-10

Applicant: FORMA Therapeutics, Inc.

Inventor： Matthew W. Martin ,  Mary-Margaret Zablocki ,  Scot Mente ,  Christopher Dinsmore ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC: C07D405/14 ,  C07D221/20 ,  C07D409/14 ,  C07D413/14 ,  C07D405/06

Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

公开(公告)号：US11299484B2

公开(公告)日：2022-04-12

申请号：US17021759

申请日：2020-09-15

Applicant: FORMA Therapeutics, Inc.

Inventor： Matthew W. Martin ,  Mary-Margaret Zablocki ,  Scot Mente ,  Christopher Dinsmore ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC: C07D405/14 ,  C07D221/20 ,  C07D409/14 ,  C07D413/14 ,  C07D405/06

Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

公开(公告)号：US11247987B2

公开(公告)日：2022-02-15

申请号：US16753439

申请日：2018-10-05

Applicant: FORMA Therapeutics, Inc.

Inventor： Justin Caravella ,  Bingsong Han ,  Cuixian Liu ,  Stephanos Ioannidis ,  Alexandre Joseph Buckmelter ,  David James Richard ,  Matthew W. Martin ,  Steven Mischke ,  Scot Mente

IPC: C07D417/04 ,  C07D417/12 ,  C07C261/04 ,  C07D231/40 ,  C07D241/04 ,  C07D265/30 ,  C07D277/46 ,  C07D277/56

Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Protease 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments. Chemical entities disclosed herein include compounds of Formula (II): wherein A, R2, R3, R4, Ra, Rc, Rd, Re, Rf, and m are defined herein.

公开(公告)号：US20210024508A1

公开(公告)日：2021-01-28

申请号：US17021759

申请日：2020-09-15

Applicant: FORMA Therapeutics, Inc.

Inventor： Matthew W. Martin ,  Mary-Margaret Zablocki ,  Scot Mente ,  Christopher Dinsmore ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC: C07D405/14 ,  C07D221/20 ,  C07D409/14 ,  C07D413/14 ,  C07D405/06

Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.